

Neuraxpharm appoints Philipp Pohoralek as new Country Manager for Germany

Europe's leading CNS specialty company strengthens its management team in Germany and reinforces its growth strategy

Dusseldorf and Barcelona, September 08, 2021 - Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today that Philipp Pohoralek has been appointed Commercial Central Region Officer and Country Manager for Germany on September 1, 2021. The appointment reinforces Neuraxpharm's management team in Germany with an experienced executive who will support the company's growth strategy for the important German market, being the largest CNS market in Europe and the fourth largest worldwide.¹

With Philipp Pohoralek, Neuraxpharm can rely on an expert in business development with a highly analytical and result-oriented profile. He has a proven track record in successfully building business for Viatris, one of the world's leading generics companies, and has extensive experience in additional product areas, including over-the-counter (OTC) drugs, biosimilars and value-added medicines. At Neuraxpharm, he will focus on strengthening the company's position in key areas, such as expanding its product portfolio in medical cannabis and in the Consumer Healthcare market.

Philipp Pohoralek combines a strong background in corporate finance with nearly ten years of experience in the pharmaceutical industry. He joins Neuraxpharm from Viatris, formerly Mylan, where he most recently served as Head of Finance Germany. In addition, he acted as Managing Director and deputy Country Manager at Viatris Germany since 2019, successfully turning the business around in the last three years. Philipp Pohoralek was Head of Finance Germany at Mylan from 2018 to 2020, having previously held similar positions for Mylan in the Netherlands from 2016 to 2018 and in Austria in 2015. He started his career in 2009 as Financial Controller at L'Oréal, before moving to the pharmaceutical industry in 2013 as Financial Planning and Analysis manager at Abbott Austria.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: *"We are very pleased to announce the appointment of Philipp Pohoralek as our new Commercial Central Region Officer and Country Manager for Germany. With his attitude, experience and fresh mindset, Philipp is a great addition to our team and will help us to become even more successful in the German market in the future. I am looking forward to working with him and to jointly expanding our position as the leading CNS company with a broad and diverse portfolio."*

Philipp Pohoralek, newly appointed Commercial Central Region Officer and Country Manager for Germany added: *"I am excited to join Neuraxpharm at such a promising time as Commercial Central Region Officer and Country Manager. Neuraxpharm offers successful and innovative products to the German market, including medical cannabis and the market-leading brand Buccolam, a value-added buccal emergency treatment for children with epilepsy. I look forward to working with my team to further expand our offering in the German market and drive the development of Neuraxpharm."*

Philipp Pohoralek will be supporting the success of several recently launched products in the German market. These include a high dosage THC extract with 250 mg/ml, which enhances Neuraxpharm's position as a provider of diversified medical cannabis products in the German market. The company also recently expanded its OTC portfolio with an alcohol-free, liquid melatonin (Seripnol Spray) with an advanced applicator.

¹ Source: IQVIA



For further information please contact:

Finsbury Glover Hering

Christian Falkowski

Tel: +49 171 86 79 950

Email: christian.falkowski@fgh.com

Optimum Strategic Communications

Mary Clark, Manuel Mateus

Tel: +44 203 950 9144

Email: neuraxpharm@optimumcomms.com

About the Group Neuraxpharm – the European CNS specialist

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in 18 countries. Backed by funds advised by Permira, Neuraxpharm has a unique understanding of the CNS market built over 35 years.

With its focus on CNS, Neuraxpharm develops and commercializes value added medicines, standard generics, and Consumer Healthcare products, e.g., probiotics and other nutraceuticals, and is continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.

Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites, Lesvi and Inke, in Spain.

To learn more about Neuraxpharm, please visit: <https://www.neuraxpharm.com/>